Stryker (NYSE:SYK) Updates FY 2026 Earnings Guidance

Stryker (NYSE:SYK) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 14.950-15.100 for the period, compared to the consensus EPS estimate of 14.980. The company issued revenue guidance of -.

Stryker Stock Down 1.1%

SYK traded down $3.88 during trading on Thursday, hitting $348.37. The company had a trading volume of 2,750,055 shares, compared to its average volume of 2,362,469. The company has a market capitalization of $133.55 billion, a PE ratio of 40.32, a PEG ratio of 2.22 and a beta of 0.77. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker has a one year low of $281.00 and a one year high of $401.99. The firm’s 50-day moving average price is $316.38 and its 200 day moving average price is $335.11.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts expect that Stryker will post 14.99 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Analyst Upgrades and Downgrades

Several research firms have commented on SYK. Citigroup cut their target price on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Truist Financial reiterated a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a report on Monday, May 4th. BMO Capital Markets assumed coverage on shares of Stryker in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective on the stock. Evercore set a $350.00 target price on shares of Stryker in a report on Monday, July 6th. Finally, Argus set a $370.00 price target on shares of Stryker in a research note on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $393.39.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 323,264 shares of company stock valued at $100,659,489 in the last 90 days. 4.60% of the stock is currently owned by insiders.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported quarterly earnings per share of $3.69, exceeding the consensus estimate of $3.49 by $0.20. Revenue reached approximately $6.59 billion, broadly ahead of expectations, while net income totaled $1.28 billion. Stryker quarterly earnings press release
• Positive Sentiment: Management said it has made progress restoring operations following the March cyberattack, suggesting disruption-related risks are becoming more manageable. Stryker Logs Higher Profit and Revenue Amid Cyberattack Recovery
• Positive Sentiment: UBS initiated coverage with a Buy rating and a $400 price target, indicating analysts see further upside based on Stryker’s medical-device portfolio and growth prospects. UBS Stryker coverage
• Positive Sentiment: The launch of the Mako RPS platform expands access to Stryker’s robotic knee-surgery technology and could support longer-term procedure growth. Stryker Launches Mako RPS
• Neutral Sentiment: Stryker maintained fiscal 2026 EPS guidance of $14.95–$15.10, with the midpoint close to analyst expectations. The update therefore provides stability but limited incremental upside.
• Negative Sentiment: Investors remain focused on the financial and operational effects of the cyberattack, while tariffs and inflation may pressure margins across medical-product manufacturers despite resilient demand. Medical product industry earnings risks

Institutional Investors Weigh In On Stryker

A number of institutional investors and hedge funds have recently modified their holdings of SYK. Brighton Jones LLC lifted its position in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the last quarter. Schnieders Capital Management LLC. bought a new position in Stryker during the second quarter worth $205,000. Marshall Wace LLP boosted its position in Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after purchasing an additional 77,831 shares during the period. Nebula Research & Development LLC acquired a new position in shares of Stryker in the second quarter valued at $219,000. Finally, HUB Investment Partners LLC bought a new position in shares of Stryker in the second quarter valued at about $253,000. 77.09% of the stock is owned by institutional investors.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.